Title:
TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2020/038415
Kind Code:
A1
Abstract:
Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.
Inventors:
LIU JING (US)
PLEWE MICHAEL BRUNO (US)
WANG JIALIANG (US)
HAN XIAORAN (CN)
CHEN LIQUN (CN)
PLEWE MICHAEL BRUNO (US)
WANG JIALIANG (US)
HAN XIAORAN (CN)
CHEN LIQUN (CN)
Application Number:
PCT/CN2019/101850
Publication Date:
February 27, 2020
Filing Date:
August 21, 2019
Export Citation:
Assignee:
CULLGEN SHANGHAI INC (CN)
International Classes:
C07D401/14; A61K31/454; A61P35/00
Domestic Patent References:
| WO2017197051A1 | 2017-11-16 | |||
| WO2017197055A1 | 2017-11-16 | |||
| WO2017197046A1 | 2017-11-16 | |||
| WO2015160845A2 | 2015-10-22 | |||
| WO2016149668A1 | 2016-09-22 | |||
| WO2019114770A1 | 2019-06-20 | |||
| WO2015160845A2 | 2015-10-22 | |||
| WO2016149668A1 | 2016-09-22 | |||
| WO2019114770A1 | 2019-06-20 |
Other References:
BAILEY，JUSTIN J.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 27, no. 7, 8 March 2017 (2017-03-08), pages 831 - 849, XP055453925, ISSN: 1354-3776, DOI: 20191111125743Y
J. BAILEY ET AL.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II", EXPERT OPIN THER PAT., vol. 27, no. 7, July 2017 (2017-07-01), pages 831 - 849, XP055453925, DOI: 10.1080/13543776.2017.1297797
JUSTIN J. BAILEY ET AL., EXPERT OPIN THER PAT., vol. 27, no. 7, July 2017 (2017-07-01), pages 831 - 849
BERGE S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
"Principles and Practice", vol. 1, article "Burger's Medicinal Chemistry and Drug Discovery"
AGUILAR, A.LU, J.LIU, L.DU, D.BERNARD, D.MCEACHERN, D.PRZYBRANOWSKI, S.LI, X.LUO, R.WEN, B. ET AL.: "Discovery of 4-((3'R,4'S,5'R)-6''-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[ cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamidojbicyclo[2.2.2]octane -1-carboxylic Acid (AA-115/APG-l 15): A Potent and Orally Active Murine Double Minute 2 (MDM2", J MED CHEM, vol. 60, 2017, pages 2819 - 2839
AMATU, A.SARTORE-BIANCHI, A.SIENA, S.: "NTRK gene fusions as novel targets of cancer therapy across multiple tumour types", ESMO OPEN, vol. 1, 2016, pages e000023
BAILEY, J.J.SCHIRRMACHER, R.FARRELL, K.BERNARD-GAUTHIER, V.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I", EXPERT OPIN THER PAT, vol. 27, 2017, pages 733 - 751, XP055453922, DOI: 10.1080/13543776.2017.1297796
BAILEY, J.J.SCHIRRMACHER, R.FARRELL, K.BERNARD-GAUTHIER, V.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II", EXPERT OPIN THER PAT, vol. 27, 2017, pages 831 - 849, XP055453925, DOI: 10.1080/13543776.2017.1297797
BLAKE, J.KOLAKOWSKI, G.R.TUCH, B.EBATA, K.BRANDHUBER, B.WINSKI, S.BOUHANA, K.NANDA, N.WU, W.I.PARKER, A. ET AL.: "The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers", EUR J CANCER, vol. 69, 2016, pages S144 - S145
BONDESON, D.P.MARES, A.SMITH, I.E.KO, E.CAMPOS, S.MIAH, A.H.MULHOLLAND, K.E.ROUTLY, N.BUCKLEY, D.L.GUSTAFSON, J.L. ET AL.: "Catalytic in vivo protein knockdown by small-molecule PROTACs", NAT CHEM BIOL, vol. 11, 2015, pages 611 - 617, XP055279063, DOI: 10.1038/nchembio.1858
BRASCA, M.G.AMBOLDI, N.BALLINARI, D.CAMERON, A.CASALE, E.CERVI, G.COLOMBO, M.COLOTTA, F.CROCI, V.D'ALESSIO, R. ET AL.: "Identification of N, 1,4,4-tetramethyl-8-1[4-(4-methylpiperazin-l-yl)phenyl]amino }-4,5-dihydro-1H-py razolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor", J MED CHEM, vol. 52, 2009, pages 5152 - 5163
BUCKLEY, D.L.CREWS, C.M.: "Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system", ANGEW CHEM INT ED ENGL, vol. 53, 2014, pages 2312 - 2330, XP055532868, DOI: 10.1002/anie.201307761
BUCKLEY, D.L.GUSTAFSON, J.L.VAN MOLLE, I.ROTH, A.G.TAE, H.S.GAREISS, P.C.JORGENSEN, W.L.CIULLI, A.CREWS, C.M.: "Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF 1 alpha", ANGEW CHEM INT ED ENGL, vol. 51, 2012, pages 11463 - 11467
BUCKLEY, D.L.RAINA, K.DARRICARRERE, N.HINES, J.GUSTAFSON, J.L.SMITH, I.E.MIAH, A.H.HARLING, J.D.CREWS, C.M.: "HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins", ACS CHEM BIOL, vol. 10, 2015, pages 1831 - 1837, XP002762672
BUCKLEY, D.L.VAN MOLLE, I.GAREISS, P.C.TAE, H.S.MICHEL, J.NOBLIN, D.J.JORGENSEN, W.L.CIULLI, A.CREWS, C.M.: "Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1 alpha interaction", J AM CHEM SOC, vol. 134, 2012, pages 4465 - 4468
CHAMBERLAIN, P.P.LOPEZ-GIRONA, A.MILLER, K.CARMEL, G.PAGARIGAN, B.CHIE-LEON, B.RYCHAK, E.CORRAL, L.G.REN, Y.J.WANG, M. ET AL.: "Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs", NAT STRUCT MOL BIOL, vol. 21, 2014, pages 803 - 809, XP055336279, DOI: 10.1038/nsmb.2874
CHOI, H.S.RUCKER, P.V.WANG, Z.FAN, Y.ALBAUGH, P.CHOPIUK, G.GESSIER, F.SUN, F.ADRIAN, F.LIU, G. ET AL.: "R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors", ACS MED CHEM LETT, vol. 6, 2015, pages 562 - 567, XP093110200, DOI: 10.1021/acsmedchemlett.5b00050
CHONG, C.R.BAHCALL, M.CAPELLETTI, M.KOSAKA, T.ERCAN, D.SIM, T.SHOLL, L.M.NISHINO, M.JOHNSON, B.E.GRAY, N.S. ET AL.: "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer", CLIN CANCER RES, vol. 23, 2017, pages 204 - 213, XP055775110, DOI: 10.1158/1078-0432.CCR-15-1601
CRANSTON, A.STOCKEN, D.D.STAMP, E.ROBLIN, D.HAMLIN, J.LANGTRY, J.PLUMMER, R.ASHWORTH, A.BURN, J.RAJAN, N.: "Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial", TRIALS, vol. 18, 2017, pages 111
CUI, J.J.ZHAI, D.DENG, W.ROGERS, E.HUANG, Z.WHITTEN, J.LI, Y.: "TPX-0005, a novel ALK/ROS 1ATRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants", EUR J CANCER, vol. 69, 2016, pages 32
DAVIES, T.G.WIXTED, W.E.COYLE, J.E.GRIFFITHS-JONES, C.HEARN, K.MCMENAMIN, R.NORTON, D.RICH, S.J.RICHARDSON, C.SAXTY, G. ET AL.: "Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery", J MED CHEM, vol. 59, 2016, pages 3991 - 4006, XP055289126, DOI: 10.1021/acs.jmedchem.6b00228
DENK, F.BENNETT, D.L.MCMAHON, S.B.: "Nerve Growth Factor and Pain Mechanisms", ANNUAL REVIEW OF NEUROSCIENCE, vol. 40, 2017, pages 307 - 325
DRILON, A.LAETSCH, T.W.KUMMAR, S.DUBOIS, S.G.LASSEN, U.N.DEMETRI, G.D.NATHENSON, M.DOEBELE, R.C.FARAGO, A.F.PAPPO, A.S. ET AL.: "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children", N ENGL J MED, vol. 378, 2018, pages 731 - 739
DRILON, A.SIENA, S.OU, S.I.PATEL, M.AHN, M.J.LEE, J.BAUER, T.M.FARAGO, A.F.WHELER, J.J.LIU, S.V. ET AL.: "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1", CANCER DISCOVERY, vol. 7, 2017, pages 400 - 409, XP055702055, DOI: 10.1158/2159-8290.CD-16-1237
E.WAKELING, A.: "Use of pure antioestrogens to elucidate the mode of action of oestrogens", BIOCHEM PHARMACOL, vol. 49, 1995, pages 1545 - 1549
FISCHER, E.S.BOHM, K.LYDEARD, J.R.YANG, H.STADLER, M.B.CAVADINI, S.NAGEL, J.SERLUCA, F.ACKER, V.LINGARAJU, G.M. ET AL.: "Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide", NATURE, vol. 512, 2014, pages 49 - 53, XP055531429, DOI: 10.1038/nature13527
FUJIWARA, Y.TAKEDA, M.YAMAMOTO, N.NAKAGAWA, K.NOSAKI, K.TOYOZAWA, R.ABE, C.SHIGA, R.NAKAMARU, K.SETO, T.: "Safety and pharmacokinetics of DS-605 1b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study", ONCOTARGET, vol. 9, 2018, pages 23729 - 23737
FUSE, M.J.OKADA, K.OH-HARA, T.OGURA, H.FUJITA, N.KATAYAMA, R.: "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers", MOL CANCER THER, vol. 16, 2017, pages 2130 - 2143
GALDEANO, C.GADD, M.S.SOARES, P.SCAFFIDI, S.VAN MOLLE, I.BIRCED, I.HEWITT, S.DIAS, D.M.CIULLI, A.: "Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities", J MED CHEM, vol. 57, 2014, pages 8657 - 8663, XP055235955, DOI: 10.1021/jm5011258
HIROYUKI SUDA, TOMOHISA TAKITA, TAKAAKI AOYAGI,UMEZAWA, H., THE JOURNAL OF ANTIBIOTIC, vol. 20, 1976, pages 100 - 101
ITO, T., ANDO, H., SUZUKI, T., OGURA, T., HOTTA, K., IMAMURA, Y., YAMAGUCHI, Y., HANDA, H.: "Identification of a primary target of thalidomide teratogenicity", SCIENCE, vol. 327, 2010, pages 1345 - 1350, XP055062167, DOI: 10.1126/science.1177319
KHOTSKAYA, Y.B., HOLLA, V.R., FARAGO, A.F., MILLS SHAW, K.R., MERIC-BERNSTAM, F., HONG, D.S.: "Targeting TRK family proteins in cancer", PHARMACOL THER, vol. 173, 2017, pages 58 - 66, XP055980316, DOI: 10.1016/j.pharmthera.2017.02.006
LAI, A.C.TOURE, M.HELLERSCHMIED, D.SALAMI, J.JAIME-FIGUEROA, S.KO, E.HINES, J.CREWS, C.M.: "Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL", ANGEW CHEM INT ED ENGL, vol. 55, 2016, pages 807 - 810, XP055734239, DOI: 10.1002/anie.201507634
LI, Z.ZHANG, Y.TONG, Y.TONG, J.THIELE, C.J.: "Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo", CANCER BIOL THER, vol. 16, 2015, pages 477 - 483
LU, J.QIAN, Y.ALTIERI, M.DONG, H.WANG, J.RAINA, K.HINES, J.WINKLER, J.D.CREW, A.P.COLEMAN, K. ET AL.: "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4", CHEMISTRY & BIOLOGY, vol. 22, 2015, pages 755 - 763, XP002774454, DOI: 10.1016/j.chembiol.2015.05.009
MANIACI, C.HUGHES, S.J.TESTA, A.CHEN, W.LAMONT, D.J.ROCHA, S.ALESSI, D.R.ROMEO, R.CIULLI, A.: "Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation", NAT COMMUN, vol. 8, 2017, pages 830, XP055476041, DOI: 10.1038/s41467-017-00954-1
MENICHINCHERI, M.ARDINI, E.MAGNAGHI, P.AVANZI, N.BANFI, P.BOSSI, R.BUFFA, L.CANEVARI, G.CERIANI, L.COLOMBO, M. ET AL.: "Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor", J MED CHEM, vol. 59, 2016, pages 3392 - 3408, XP055663585, DOI: 10.1021/acs.jmedchem.6b00064
MILLER, R.E.BLOCK, J.A.MALFAIT, A.M.: "Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?", CURRENT OPINION IN RHEUMATOLOGY, vol. 29, 2017, pages 110 - 118
OHOKA, N.OKUHIRA, K.ITO, M.NAGAI, K.SHIBATA, N.HATTORI, T.UJIKAWA, O.SHIMOKAWA, K.SANO, O.KOYAMA, R. ET AL.: "In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs", J BIOL CHEM, vol. 292, 2017, pages 4556 - 4570, XP055691447, DOI: 10.1074/jbc.M116.768853
OKUHIRA, K.OHOKA, N.SAI, K.NISHIMAKI-MOGAMI, T.ITOH, Y.ISHIKAWA, M.HASHIMOTO, Y.NAITO, M.: "Specific degradation of CRABP-II via cIAPI-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP 1 and the target protein", FEBS LETT, vol. 585, 2011, pages 1147 - 1152
PATWARDHAN, P.P.IVY, K.S.MUSI, E.DE STANCHINA, E.SCHWARTZ, G.K.: "Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma", ONCOTARGET, vol. 7, 2016, pages 4093 - 4109
RICCIUTI, B., BRAMBILLA, M., METRO, G., BAGLIVO, S., MATOCCI, R., PIRRO, M.,CHIARI, R.: "Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence", MED ONCOL, vol. 34, 2017, pages 105
SCHNITZER, T.J.MARKS, J.A.: "A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee", OSTEOARTHRITIS AND CARTILAGE, vol. 23, no. 1, 2015, pages 8 - 17
SHIBATA, N.MIYAMOTO, N.NAGAI, K.SHIMOKAWA, K.SAMESHIMA, T.OHOKA, N.HATTORI, T.IMAEDA, Y.NARA, H.CHO, N. ET AL.: "Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands", CANCER SCI, vol. 108, 2017, pages 1657 - 1666, XP055501430, DOI: 10.1111/cas.13284
SKERRATT, S.E.ANDREWS, M.BAGAL, S.K.BILSLAND, J.BROWN, D.BUNGAY, P.J.COLE, S.GIBSON, K.R.JONES, R.MORAO, I. ET AL.: "The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain", J MED CHEM, vol. 59, 2016, pages 10084 - 10099
SMITH, B.D.KAUFMAN, M.D.LEARY, C.B.TURNER, B.A.WISE, S.C.AHN, Y.M.BOOTH, R.J.CALDWELL, T.M.ENSINGER, C.L.HOOD, M.M. ET AL.: "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2", MOL CANCER THER, vol. 14, 2015, pages 2023 - 2034
SUBBIAH, V.KHAWAJA, M.R.HONG, D.S.AMINI, B.YUNGFANG, J.LIU, H.JOHNSON, A.SCHROCK, A.B.ALI, S.M.SUN, J.X. ET AL.: "First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients", JCI INSIGHT, vol. 2, 2017
SUN, D.LI, Z.REW, Y.GRIBBLE, M.BARTBERGER, M.D.BECK, H.P.CANON, J.CHEN, A.CHEN, X.CHOW, D. ET AL.: "Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development", J MED CHEM, vol. 57, 2014, pages 1454 - 1472, XP055116592, DOI: 10.1021/jm401753e
TATEMATSU, T.SASAKI, H.SHIMIZU, S.OKUDA, K.SHITARA, M.HIKOSAKA, Y.MORIYAMA, S.YANO, M.BROWN, J.FUJII, Y.: "Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro", MOL CLIN ONCOL, vol. 2, 2014, pages 725 - 730, XP093087025, DOI: 10.3892/mco.2014.318
VARFOLOMEEV, E.BLANKENSHIP, J.W.WAYSON, S.M.FEDOROVA, A.V.KAYAGAKI, N.GARG, P.ZOBEL, K.DYNEK, J.N.ELLIOTT, L.O.WALLWEBER, H.J. ET : "IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis", CELL, vol. 131, 2007, pages 669 - 681
VASSILEV, L.T.VU, B.T.GRAVES, B.CARVAJAL, D.PODLASKI, F.FILIPOVIC, Z.KONG, N.KAMMLOTT, U.LUKACS, C.KLEIN, C. ET AL.: "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2", SCIENCE, vol. 303, 2004, pages 844 - 848, XP002338500, DOI: 10.1126/science.1092472
VU, B.WOVKULICH, P.PIZZOLATO, G.LOVEY, A.DING, Q.JIANG, N.LIU, J.J.ZHAO, C.GLENN, K.WEN, Y. ET AL.: "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development", ACS MED CHEM LETT, vol. 4, 2013, pages 466 - 469, XP055567750, DOI: 10.1021/ml4000657
WEISBERG, E.RAY, A.BARRETT, R.NELSON, E.CHRISTIE, A.L.PORTER, D.STRAUB, C.ZAWEL, L.DALEY, J.F.LAZO-KALLANIAN, S. ET AL.: "Smac mimetics: implications for enhancement of targeted therapies in leukemia", LEUKEMIA, vol. 24, 2010, pages 2100 - 2109, XP037785237, DOI: 10.1038/leu.2010.212
WINTER, G.E., BUCKLEY, D.L., PAULK, J., ROBERTS, J.M., SOUZA, A., DHE-PAGANON, S.,BRADNER, J.E.: "Phthalimide conjugation as a strategy for in vivo target protein degradation", SCIENCE, vol. 348, 2015, pages 1376 - 1381, XP055328122, DOI: 10.1126/science.aab1433
XIE, T.LIM, S.M.WESTOVER, K.D.DODGE, M.E.ERCAN, D.FICARRO, S.B.UDAYAKUMAR, D.GURBANI, D.TAE, H.S.RIDDLE, S.M. ET AL.: "Pharmacological targeting of the pseudokinase Her3", NAT CHEM BIOL, vol. 10, 2014, pages 1006 - 1012, XP055693096, DOI: 10.1038/nchembio.1658
ZENGERLE, M.CHAN, K.H.CIULLI, A.: "Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4", ACS CHEM BIOL, vol. 10, 2015, pages 1770 - 1777, XP055333869, DOI: 10.1021/acschembio.5b00216
See also references of EP 3841098A4
J. BAILEY ET AL.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II", EXPERT OPIN THER PAT., vol. 27, no. 7, July 2017 (2017-07-01), pages 831 - 849, XP055453925, DOI: 10.1080/13543776.2017.1297797
JUSTIN J. BAILEY ET AL., EXPERT OPIN THER PAT., vol. 27, no. 7, July 2017 (2017-07-01), pages 831 - 849
BERGE S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
"Principles and Practice", vol. 1, article "Burger's Medicinal Chemistry and Drug Discovery"
AGUILAR, A.LU, J.LIU, L.DU, D.BERNARD, D.MCEACHERN, D.PRZYBRANOWSKI, S.LI, X.LUO, R.WEN, B. ET AL.: "Discovery of 4-((3'R,4'S,5'R)-6''-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[ cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamidojbicyclo[2.2.2]octane -1-carboxylic Acid (AA-115/APG-l 15): A Potent and Orally Active Murine Double Minute 2 (MDM2", J MED CHEM, vol. 60, 2017, pages 2819 - 2839
AMATU, A.SARTORE-BIANCHI, A.SIENA, S.: "NTRK gene fusions as novel targets of cancer therapy across multiple tumour types", ESMO OPEN, vol. 1, 2016, pages e000023
BAILEY, J.J.SCHIRRMACHER, R.FARRELL, K.BERNARD-GAUTHIER, V.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I", EXPERT OPIN THER PAT, vol. 27, 2017, pages 733 - 751, XP055453922, DOI: 10.1080/13543776.2017.1297796
BAILEY, J.J.SCHIRRMACHER, R.FARRELL, K.BERNARD-GAUTHIER, V.: "Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II", EXPERT OPIN THER PAT, vol. 27, 2017, pages 831 - 849, XP055453925, DOI: 10.1080/13543776.2017.1297797
BLAKE, J.KOLAKOWSKI, G.R.TUCH, B.EBATA, K.BRANDHUBER, B.WINSKI, S.BOUHANA, K.NANDA, N.WU, W.I.PARKER, A. ET AL.: "The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers", EUR J CANCER, vol. 69, 2016, pages S144 - S145
BONDESON, D.P.MARES, A.SMITH, I.E.KO, E.CAMPOS, S.MIAH, A.H.MULHOLLAND, K.E.ROUTLY, N.BUCKLEY, D.L.GUSTAFSON, J.L. ET AL.: "Catalytic in vivo protein knockdown by small-molecule PROTACs", NAT CHEM BIOL, vol. 11, 2015, pages 611 - 617, XP055279063, DOI: 10.1038/nchembio.1858
BRASCA, M.G.AMBOLDI, N.BALLINARI, D.CAMERON, A.CASALE, E.CERVI, G.COLOMBO, M.COLOTTA, F.CROCI, V.D'ALESSIO, R. ET AL.: "Identification of N, 1,4,4-tetramethyl-8-1[4-(4-methylpiperazin-l-yl)phenyl]amino }-4,5-dihydro-1H-py razolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor", J MED CHEM, vol. 52, 2009, pages 5152 - 5163
BUCKLEY, D.L.CREWS, C.M.: "Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system", ANGEW CHEM INT ED ENGL, vol. 53, 2014, pages 2312 - 2330, XP055532868, DOI: 10.1002/anie.201307761
BUCKLEY, D.L.GUSTAFSON, J.L.VAN MOLLE, I.ROTH, A.G.TAE, H.S.GAREISS, P.C.JORGENSEN, W.L.CIULLI, A.CREWS, C.M.: "Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF 1 alpha", ANGEW CHEM INT ED ENGL, vol. 51, 2012, pages 11463 - 11467
BUCKLEY, D.L.RAINA, K.DARRICARRERE, N.HINES, J.GUSTAFSON, J.L.SMITH, I.E.MIAH, A.H.HARLING, J.D.CREWS, C.M.: "HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins", ACS CHEM BIOL, vol. 10, 2015, pages 1831 - 1837, XP002762672
BUCKLEY, D.L.VAN MOLLE, I.GAREISS, P.C.TAE, H.S.MICHEL, J.NOBLIN, D.J.JORGENSEN, W.L.CIULLI, A.CREWS, C.M.: "Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1 alpha interaction", J AM CHEM SOC, vol. 134, 2012, pages 4465 - 4468
CHAMBERLAIN, P.P.LOPEZ-GIRONA, A.MILLER, K.CARMEL, G.PAGARIGAN, B.CHIE-LEON, B.RYCHAK, E.CORRAL, L.G.REN, Y.J.WANG, M. ET AL.: "Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs", NAT STRUCT MOL BIOL, vol. 21, 2014, pages 803 - 809, XP055336279, DOI: 10.1038/nsmb.2874
CHOI, H.S.RUCKER, P.V.WANG, Z.FAN, Y.ALBAUGH, P.CHOPIUK, G.GESSIER, F.SUN, F.ADRIAN, F.LIU, G. ET AL.: "R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors", ACS MED CHEM LETT, vol. 6, 2015, pages 562 - 567, XP093110200, DOI: 10.1021/acsmedchemlett.5b00050
CHONG, C.R.BAHCALL, M.CAPELLETTI, M.KOSAKA, T.ERCAN, D.SIM, T.SHOLL, L.M.NISHINO, M.JOHNSON, B.E.GRAY, N.S. ET AL.: "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer", CLIN CANCER RES, vol. 23, 2017, pages 204 - 213, XP055775110, DOI: 10.1158/1078-0432.CCR-15-1601
CRANSTON, A.STOCKEN, D.D.STAMP, E.ROBLIN, D.HAMLIN, J.LANGTRY, J.PLUMMER, R.ASHWORTH, A.BURN, J.RAJAN, N.: "Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial", TRIALS, vol. 18, 2017, pages 111
CUI, J.J.ZHAI, D.DENG, W.ROGERS, E.HUANG, Z.WHITTEN, J.LI, Y.: "TPX-0005, a novel ALK/ROS 1ATRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants", EUR J CANCER, vol. 69, 2016, pages 32
DAVIES, T.G.WIXTED, W.E.COYLE, J.E.GRIFFITHS-JONES, C.HEARN, K.MCMENAMIN, R.NORTON, D.RICH, S.J.RICHARDSON, C.SAXTY, G. ET AL.: "Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery", J MED CHEM, vol. 59, 2016, pages 3991 - 4006, XP055289126, DOI: 10.1021/acs.jmedchem.6b00228
DENK, F.BENNETT, D.L.MCMAHON, S.B.: "Nerve Growth Factor and Pain Mechanisms", ANNUAL REVIEW OF NEUROSCIENCE, vol. 40, 2017, pages 307 - 325
DRILON, A.LAETSCH, T.W.KUMMAR, S.DUBOIS, S.G.LASSEN, U.N.DEMETRI, G.D.NATHENSON, M.DOEBELE, R.C.FARAGO, A.F.PAPPO, A.S. ET AL.: "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children", N ENGL J MED, vol. 378, 2018, pages 731 - 739
DRILON, A.SIENA, S.OU, S.I.PATEL, M.AHN, M.J.LEE, J.BAUER, T.M.FARAGO, A.F.WHELER, J.J.LIU, S.V. ET AL.: "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1", CANCER DISCOVERY, vol. 7, 2017, pages 400 - 409, XP055702055, DOI: 10.1158/2159-8290.CD-16-1237
E.WAKELING, A.: "Use of pure antioestrogens to elucidate the mode of action of oestrogens", BIOCHEM PHARMACOL, vol. 49, 1995, pages 1545 - 1549
FISCHER, E.S.BOHM, K.LYDEARD, J.R.YANG, H.STADLER, M.B.CAVADINI, S.NAGEL, J.SERLUCA, F.ACKER, V.LINGARAJU, G.M. ET AL.: "Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide", NATURE, vol. 512, 2014, pages 49 - 53, XP055531429, DOI: 10.1038/nature13527
FUJIWARA, Y.TAKEDA, M.YAMAMOTO, N.NAKAGAWA, K.NOSAKI, K.TOYOZAWA, R.ABE, C.SHIGA, R.NAKAMARU, K.SETO, T.: "Safety and pharmacokinetics of DS-605 1b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study", ONCOTARGET, vol. 9, 2018, pages 23729 - 23737
FUSE, M.J.OKADA, K.OH-HARA, T.OGURA, H.FUJITA, N.KATAYAMA, R.: "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers", MOL CANCER THER, vol. 16, 2017, pages 2130 - 2143
GALDEANO, C.GADD, M.S.SOARES, P.SCAFFIDI, S.VAN MOLLE, I.BIRCED, I.HEWITT, S.DIAS, D.M.CIULLI, A.: "Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities", J MED CHEM, vol. 57, 2014, pages 8657 - 8663, XP055235955, DOI: 10.1021/jm5011258
HIROYUKI SUDA, TOMOHISA TAKITA, TAKAAKI AOYAGI,UMEZAWA, H., THE JOURNAL OF ANTIBIOTIC, vol. 20, 1976, pages 100 - 101
ITO, T., ANDO, H., SUZUKI, T., OGURA, T., HOTTA, K., IMAMURA, Y., YAMAGUCHI, Y., HANDA, H.: "Identification of a primary target of thalidomide teratogenicity", SCIENCE, vol. 327, 2010, pages 1345 - 1350, XP055062167, DOI: 10.1126/science.1177319
KHOTSKAYA, Y.B., HOLLA, V.R., FARAGO, A.F., MILLS SHAW, K.R., MERIC-BERNSTAM, F., HONG, D.S.: "Targeting TRK family proteins in cancer", PHARMACOL THER, vol. 173, 2017, pages 58 - 66, XP055980316, DOI: 10.1016/j.pharmthera.2017.02.006
LAI, A.C.TOURE, M.HELLERSCHMIED, D.SALAMI, J.JAIME-FIGUEROA, S.KO, E.HINES, J.CREWS, C.M.: "Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL", ANGEW CHEM INT ED ENGL, vol. 55, 2016, pages 807 - 810, XP055734239, DOI: 10.1002/anie.201507634
LI, Z.ZHANG, Y.TONG, Y.TONG, J.THIELE, C.J.: "Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo", CANCER BIOL THER, vol. 16, 2015, pages 477 - 483
LU, J.QIAN, Y.ALTIERI, M.DONG, H.WANG, J.RAINA, K.HINES, J.WINKLER, J.D.CREW, A.P.COLEMAN, K. ET AL.: "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4", CHEMISTRY & BIOLOGY, vol. 22, 2015, pages 755 - 763, XP002774454, DOI: 10.1016/j.chembiol.2015.05.009
MANIACI, C.HUGHES, S.J.TESTA, A.CHEN, W.LAMONT, D.J.ROCHA, S.ALESSI, D.R.ROMEO, R.CIULLI, A.: "Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation", NAT COMMUN, vol. 8, 2017, pages 830, XP055476041, DOI: 10.1038/s41467-017-00954-1
MENICHINCHERI, M.ARDINI, E.MAGNAGHI, P.AVANZI, N.BANFI, P.BOSSI, R.BUFFA, L.CANEVARI, G.CERIANI, L.COLOMBO, M. ET AL.: "Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor", J MED CHEM, vol. 59, 2016, pages 3392 - 3408, XP055663585, DOI: 10.1021/acs.jmedchem.6b00064
MILLER, R.E.BLOCK, J.A.MALFAIT, A.M.: "Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?", CURRENT OPINION IN RHEUMATOLOGY, vol. 29, 2017, pages 110 - 118
OHOKA, N.OKUHIRA, K.ITO, M.NAGAI, K.SHIBATA, N.HATTORI, T.UJIKAWA, O.SHIMOKAWA, K.SANO, O.KOYAMA, R. ET AL.: "In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs", J BIOL CHEM, vol. 292, 2017, pages 4556 - 4570, XP055691447, DOI: 10.1074/jbc.M116.768853
OKUHIRA, K.OHOKA, N.SAI, K.NISHIMAKI-MOGAMI, T.ITOH, Y.ISHIKAWA, M.HASHIMOTO, Y.NAITO, M.: "Specific degradation of CRABP-II via cIAPI-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP 1 and the target protein", FEBS LETT, vol. 585, 2011, pages 1147 - 1152
PATWARDHAN, P.P.IVY, K.S.MUSI, E.DE STANCHINA, E.SCHWARTZ, G.K.: "Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma", ONCOTARGET, vol. 7, 2016, pages 4093 - 4109
RICCIUTI, B., BRAMBILLA, M., METRO, G., BAGLIVO, S., MATOCCI, R., PIRRO, M.,CHIARI, R.: "Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence", MED ONCOL, vol. 34, 2017, pages 105
SCHNITZER, T.J.MARKS, J.A.: "A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee", OSTEOARTHRITIS AND CARTILAGE, vol. 23, no. 1, 2015, pages 8 - 17
SHIBATA, N.MIYAMOTO, N.NAGAI, K.SHIMOKAWA, K.SAMESHIMA, T.OHOKA, N.HATTORI, T.IMAEDA, Y.NARA, H.CHO, N. ET AL.: "Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands", CANCER SCI, vol. 108, 2017, pages 1657 - 1666, XP055501430, DOI: 10.1111/cas.13284
SKERRATT, S.E.ANDREWS, M.BAGAL, S.K.BILSLAND, J.BROWN, D.BUNGAY, P.J.COLE, S.GIBSON, K.R.JONES, R.MORAO, I. ET AL.: "The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain", J MED CHEM, vol. 59, 2016, pages 10084 - 10099
SMITH, B.D.KAUFMAN, M.D.LEARY, C.B.TURNER, B.A.WISE, S.C.AHN, Y.M.BOOTH, R.J.CALDWELL, T.M.ENSINGER, C.L.HOOD, M.M. ET AL.: "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2", MOL CANCER THER, vol. 14, 2015, pages 2023 - 2034
SUBBIAH, V.KHAWAJA, M.R.HONG, D.S.AMINI, B.YUNGFANG, J.LIU, H.JOHNSON, A.SCHROCK, A.B.ALI, S.M.SUN, J.X. ET AL.: "First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients", JCI INSIGHT, vol. 2, 2017
SUN, D.LI, Z.REW, Y.GRIBBLE, M.BARTBERGER, M.D.BECK, H.P.CANON, J.CHEN, A.CHEN, X.CHOW, D. ET AL.: "Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development", J MED CHEM, vol. 57, 2014, pages 1454 - 1472, XP055116592, DOI: 10.1021/jm401753e
TATEMATSU, T.SASAKI, H.SHIMIZU, S.OKUDA, K.SHITARA, M.HIKOSAKA, Y.MORIYAMA, S.YANO, M.BROWN, J.FUJII, Y.: "Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro", MOL CLIN ONCOL, vol. 2, 2014, pages 725 - 730, XP093087025, DOI: 10.3892/mco.2014.318
VARFOLOMEEV, E.BLANKENSHIP, J.W.WAYSON, S.M.FEDOROVA, A.V.KAYAGAKI, N.GARG, P.ZOBEL, K.DYNEK, J.N.ELLIOTT, L.O.WALLWEBER, H.J. ET : "IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis", CELL, vol. 131, 2007, pages 669 - 681
VASSILEV, L.T.VU, B.T.GRAVES, B.CARVAJAL, D.PODLASKI, F.FILIPOVIC, Z.KONG, N.KAMMLOTT, U.LUKACS, C.KLEIN, C. ET AL.: "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2", SCIENCE, vol. 303, 2004, pages 844 - 848, XP002338500, DOI: 10.1126/science.1092472
VU, B.WOVKULICH, P.PIZZOLATO, G.LOVEY, A.DING, Q.JIANG, N.LIU, J.J.ZHAO, C.GLENN, K.WEN, Y. ET AL.: "Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development", ACS MED CHEM LETT, vol. 4, 2013, pages 466 - 469, XP055567750, DOI: 10.1021/ml4000657
WEISBERG, E.RAY, A.BARRETT, R.NELSON, E.CHRISTIE, A.L.PORTER, D.STRAUB, C.ZAWEL, L.DALEY, J.F.LAZO-KALLANIAN, S. ET AL.: "Smac mimetics: implications for enhancement of targeted therapies in leukemia", LEUKEMIA, vol. 24, 2010, pages 2100 - 2109, XP037785237, DOI: 10.1038/leu.2010.212
WINTER, G.E., BUCKLEY, D.L., PAULK, J., ROBERTS, J.M., SOUZA, A., DHE-PAGANON, S.,BRADNER, J.E.: "Phthalimide conjugation as a strategy for in vivo target protein degradation", SCIENCE, vol. 348, 2015, pages 1376 - 1381, XP055328122, DOI: 10.1126/science.aab1433
XIE, T.LIM, S.M.WESTOVER, K.D.DODGE, M.E.ERCAN, D.FICARRO, S.B.UDAYAKUMAR, D.GURBANI, D.TAE, H.S.RIDDLE, S.M. ET AL.: "Pharmacological targeting of the pseudokinase Her3", NAT CHEM BIOL, vol. 10, 2014, pages 1006 - 1012, XP055693096, DOI: 10.1038/nchembio.1658
ZENGERLE, M.CHAN, K.H.CIULLI, A.: "Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4", ACS CHEM BIOL, vol. 10, 2015, pages 1770 - 1777, XP055333869, DOI: 10.1021/acschembio.5b00216
See also references of EP 3841098A4
Attorney, Agent or Firm:
AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: